PURPOSE: To assess clinicopathologic features and postresection survival of diabetes mellitus (DM)-associated pancreatic ductal adenocarcinoma (PDAC). METHODS: Records of resected PDAC patients from 2000 to 2007 were reviewed. DM was classified as new-onset (<24 months before PDAC) or longstanding (> or =24 months). Clinicopathologic features were compared by univariate and multivariate analyses. Survival was assessed by Kaplan-Meier method and Cox regression. RESULTS: Of 209 patients, 93 (45%) met criteria for DM (35 longstanding DM, 55 new-onset DM, 3 duration unknown). DM patients were older (DM 66 +/- 9 years, non-DM 63 +/- 12 years, P = 0.06); a majority had additional preoperative comorbidities (DM 64.5%, non-DM 25.9%, P < 0.001). Tumor size was larger in patients with DM (DM 3.8 +/- 1.7 cm, non-DM 3.2 +/- 1.5 cm, P = 0.003). Groups were similar in terms of tumor location, perineural/lymphovascular invasion, and node and margin status. On logistic regression, tumor size >/=3.0 cm was independently associated with both overall DM (odds ratio [OR] 3.60; 95% confidence interval [1.79-7.26]) and new-onset DM (OR 3.69, [1.65-8.24]). Median survival was reduced in patients with DM compared with non-DM (15 versus 17 months, P = 0.015). Multivariate analysis controlling for prognostic variables including age, comorbidities, and tumor size demonstrated that DM was independently associated with reduced survival (hazard ratio [HR] 1.55, [1.02-2.35]). This association was more pronounced for patients with new-onset DM (HR 1.75 [1.10-2.78]) than those with longstanding DM (HR 1.30 [0.75-2.25]). CONCLUSIONS: Preexisting DM is associated with reduced survival in patients undergoing resection for PDAC. PDAC with new-onset DM may exhibit increased tumor size and decreased postresection survival. Additional investigation is needed to clarify etiology and impact of PDAC-associated DM.
PURPOSE: To assess clinicopathologic features and postresection survival of diabetes mellitus (DM)-associated pancreatic ductal adenocarcinoma (PDAC). METHODS: Records of resected PDACpatients from 2000 to 2007 were reviewed. DM was classified as new-onset (<24 months before PDAC) or longstanding (> or =24 months). Clinicopathologic features were compared by univariate and multivariate analyses. Survival was assessed by Kaplan-Meier method and Cox regression. RESULTS: Of 209 patients, 93 (45%) met criteria for DM (35 longstanding DM, 55 new-onset DM, 3 duration unknown). DMpatients were older (DM 66 +/- 9 years, non-DM 63 +/- 12 years, P = 0.06); a majority had additional preoperative comorbidities (DM 64.5%, non-DM 25.9%, P < 0.001). Tumor size was larger in patients with DM (DM 3.8 +/- 1.7 cm, non-DM 3.2 +/- 1.5 cm, P = 0.003). Groups were similar in terms of tumor location, perineural/lymphovascular invasion, and node and margin status. On logistic regression, tumor size >/=3.0 cm was independently associated with both overall DM (odds ratio [OR] 3.60; 95% confidence interval [1.79-7.26]) and new-onset DM (OR 3.69, [1.65-8.24]). Median survival was reduced in patients with DM compared with non-DM (15 versus 17 months, P = 0.015). Multivariate analysis controlling for prognostic variables including age, comorbidities, and tumor size demonstrated that DM was independently associated with reduced survival (hazard ratio [HR] 1.55, [1.02-2.35]). This association was more pronounced for patients with new-onset DM (HR 1.75 [1.10-2.78]) than those with longstanding DM (HR 1.30 [0.75-2.25]). CONCLUSIONS: Preexisting DM is associated with reduced survival in patients undergoing resection for PDAC. PDAC with new-onset DM may exhibit increased tumor size and decreased postresection survival. Additional investigation is needed to clarify etiology and impact of PDAC-associated DM.
Authors: Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins Journal: HPB (Oxford) Date: 2012-01-19 Impact factor: 3.647
Authors: Christie Y Jeon; Donghui Li; Sean Cleary; Rachael Stolzenberg-Solomon; Cristina Bosetti; Carlo La Vecchia; Miquel Porta; Adetunji T Toriola; Rayjean J Hung; Robert C Kurtz; Sara H Olson Journal: Pancreas Date: 2018-03 Impact factor: 3.327
Authors: Clement L K Chia; Anthea Y S Lee; Vishal G Shelat; Saleem Ahmed; Sameer P Junnarkar; Winston W L Woon; Jee-Keem Low Journal: Hepatobiliary Surg Nutr Date: 2016-02 Impact factor: 7.293
Authors: E S Paul Rajamanickam; K K Christians; M Aldakkak; A N Krepline; P S Ritch; B George; B A Erickson; W D Foley; M Aburajab; D B Evans; S Tsai Journal: J Gastrointest Surg Date: 2016-11-28 Impact factor: 3.452
Authors: Chen Yuan; Douglas A Rubinson; Zhi Rong Qian; Chen Wu; Peter Kraft; Ying Bao; Shuji Ogino; Kimmie Ng; Thomas E Clancy; Richard S Swanson; Megan J Gorman; Lauren K Brais; Tingting Li; Meir J Stampfer; Frank B Hu; Edward L Giovannucci; Matthew H Kulke; Charles S Fuchs; Brian M Wolpin Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Sophie Cai; Theodore S Hong; Saveli I Goldberg; Carlos Fernandez-del Castillo; Sarah P Thayer; Cristina R Ferrone; David P Ryan; Lawrence S Blaszkowsky; Eunice L Kwak; Christopher G Willett; Keith D Lillemoe; Andrew L Warshaw; Jennifer Y Wo Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: Donghui Li; Yixiang Mao; Ping Chang; Chang Liu; Manal M Hassan; Saiching J Yeung; James L Abbruzzese Journal: Am J Cancer Res Date: 2015-09-15 Impact factor: 6.166
Authors: Ivana Dzeletovic; M Edwyn Harrison; Michael D Crowell; Rahul Pannala; Cuong C Nguyen; Qing Wu; Douglas O Faigel Journal: J Clin Gastroenterol Date: 2014-10 Impact factor: 3.062